Contact Us and Locations

About Us

Delivering the future of Immunology

  • About Us
  • Contact Us

Contact us

  • HQ NanoMab Center
  • Beauty Center AIMCE Center
  • Pre-clinical Center
  • Hudson Therapeutics, Inc.
  • HQ/NanoMab Center Gangnam Ace Tower G9

    • Suites 218 & 606, 174-10, Jagok-ro, Gangnam-gu, Seoul, Republic of Korea

    • Tel. 02 6083 8315
  • Beauty Center/AIMCE Center

    • Suites 419-425, 172, Jagok-ro, Gangnam-gu, Seoul, Republic of Korea

  • Pre-clinical Center

    • A-1A10, WRII, 101, Dabyeonbat-gil, Hwachon-myeon, Hongcheon-gun, Gangwon-do, Republic of Korea

  • Hudson Therapeutics, Inc.

    • 15 TW Alexander Drive, Durham, NC 27709, USA

Consultation Request

If you are interested in our pipeline or seeking a business partnership,
please fill out the form below, and we will get in touch with you.

Contact

Name*

Phone*

E-mail*

Message*

Privacy Policy

Shaperon (the "Company") discloses this Privacy Policy in accordance with the Personal Information Protection Act of Korea to protect personal information and promptly handle related concerns.

Article 1. Purpose, Items and Retention
1. Inquiries
 - Purpose: reviewing and answering inquiries
 - Items: name, phone number, e-mail address, topic, message, IP address
 - Retention: 3 years after the inquiry is closed
2. Job applications
 - Purpose: conducting the hiring process
 - Items: information entered in the application form
 - Retention: 180 days after the hiring process ends
3. Site analytics
 - Purpose: improving the website
 - Items: cookies, visit records
 - Retention: the period set in Google Analytics
HR inquiries from the Careers page are forwarded to the HR mailbox and are not stored on this website. The Company does not store questions asked in the AI Assistant. Please do not enter personal information such as your name or phone number in the AI Assistant.

Article 2. Provision to Third Parties
The Company does not provide personal information to third parties beyond the scope of Article 1, except where required by law.

Article 3. Outsourcing and Overseas Transfer
The Company outsources the processing of personal information as follows.
 - Cloudflare, Inc. (USA): website operation, inquiry storage
 - Anthropic, PBC (USA): spam screening, AI Assistant
 - Google LLC (USA): e-mail delivery, site analytics
Inquiry items, AI Assistant questions and visit records in Article 1 are transmitted to these companies over the network when you use the service, and are processed until the outsourcing contract ends or the retention period in Article 1 expires. If you do not wish your information to be transferred overseas, you may contact us by phone instead of using the inquiry forms and the AI Assistant.

Article 4. Destruction
The Company destroys personal information without delay when the retention period ends or the purpose has been achieved. Electronic files are deleted so that they cannot be recovered, and paper documents are shredded or incinerated. Information that must be preserved by law is stored separately.

Article 5. Your Rights
You may request access to, correction or deletion of, or suspension of processing of your personal information using the contact details in Article 8, and the Company will act without delay. You may also make a request through a legal representative or authorized person.

Article 6. Security Measures
 - Access to the admin screen is limited to staff registered with a company account.
 - Access is managed through separate administrator and editor permissions.
 - Data in transit is encrypted with HTTPS.
 - Automated submissions are blocked by a bot check.

Article 7. Cookies
The Company uses Google Analytics cookies for site analytics. Providers of embedded maps, videos and bot checks may also set cookies. You may refuse cookies in your browser settings, but some features may be limited.

Article 8. Privacy Department
 - Department: Management Innovation Team
 - Phone: +82-2-6083-8315

Article 9. Remedies
 - Personal Information Dispute Mediation Committee: 1833-6972 (www.kopico.go.kr)
 - Personal Information Infringement Report Center: 118 (privacy.kisa.or.kr)
 - Supreme Prosecutors' Office: 1301 (www.spo.go.kr)
 - National Police Agency: 182 (ecrm.police.go.kr)

Article 10. Changes
This Privacy Policy takes effect on November 5, 2026.

NuGel

Addressing the Root Cause of Atopic Dermatitis
to Restore Skin Health and Reduce Daily Burden

  • Competitiveness

    • First-in-class GPCR19-targeting anti-inflammatory therapy, offering a novel mechanism of action beyond existing PDE4 inhibitors, JAK inhibitors, and steroid-based treatments
    • Simultaneous inhibition of sensitization (Priming) and activation, demonstrating differentiated anti-inflammatory efficacy compared to existing therapies
    • Improvement in key atopic dermatitis clinical endpoints, including EASI and vIGA, with no rebound observed after treatment discontinuation
    • GPCR19-mediated immune modulation minimizes systemic toxicity and adverse effects, supporting long-term use
    • Biomarker-based approach toward personalized treatment tailored to individual patient characteristics
  • Market Outlook

    • Approximately 170 million patients worldwide with atopic dermatitis (Prevalence: ~10% in children, ~3% in adults)
    • Global market size projected at USD 13 billion by 2025, with a CAGR of 16.4%, and expected to reach USD 33 billion by 2030
    • Limitations and adverse effects of existing PDE4 and JAK inhibitors are driving demand for new therapeutic options
  • Unmet Need

    • Lack of safe and effective long-term topical therapies for patients with mild to moderate atopic dermatitis
    • NuGel is positioned as a new standard-of-care candidate addressing this unmet need
  • Development Status

    • Phase 2a clinical trial completed in Korea, demonstrating improvement in EASI and vIGA scores as well as safety
    • Phase 2b clinical trial approved by the U.S. FDA (177 patients, 12-week treatment period) - ongoing
    • Global Phase 2b trial expected to conclude in 2026, with active out-licensing discussions underway
    • Preparation underway for commercialization as a prescription topical therapy
  • EASI*Eczema Area and Severity Index, a composite score evaluating the extent and severity of atopic dermatitis
  • EASI-50*≥50% improvement in EASI score from baseline
  • vIGA*Investigator’s Global Assessment, a 0-4 scale evaluating overall disease severity

Precision Medicine-Based Therapeutic Development:
Identification of Biomarkers Predictive of NuGel Responders

NuGel research data 1
NuGel research data 2

Distinct Efficacy of NuGel Confirmed in Biomarker-Positive Patients

NuGel research data 3
NuGel research data 4

Based on the results of Part 1 of a Phase 2b clinical trial,

NuGel shows great efficacy with atopic dermatitis
patients achieving 100% of EASI-50 in subgroup

NuGel research data 5
NuGel research data 6

NuDifin

Suppressing Inflammation at the Wound Site
to Accelerate Tissue Repair and Regeneration

  • Competitiveness

    • First-in-class GPCR19-targeting anti-inflammatory therapy that fundamentally modulates chronic inflammation and immune imbalance in non-healing wounds
    • Superior tissue penetration, safety, and cost competitiveness compared to growth factor-based therapies such as EGF and PDGF
    • Promotion of wound healing in chronic inflammatory conditions through inhibition of NLRP3 inflammasome activation and NETosis
    • Preclinical data demonstrating improved wound contraction and tissue regeneration compared to EGF
  • Market Outlook

    • The global diabetic population is projected to reach 850 million by 2025 and 1.2 billion by 2050
    • Approximately 19-34% of diabetic patients are expected to experience diabetic foot ulcers (DFUs) during their lifetime, with 9-26 million new cases annually
    • High rates of amputation and mortality associated with treatment failure are driving demand for safe and effective next-generation therapies
    • Limitations of growth factor therapies (low clinical success rates and high costs) are creating opportunities for inflammation-modulating wound therapeutics
  • Unmet Need

    • Existing growth factor-based treatments show variable efficacy, limited tissue penetration, high costs, and potential cancer risk
    • Therapeutic options remain limited for infected or recurrent DFUs
    • There is a lack of treatments capable of preventing recurrence through fundamental control of chronic inflammation
    • NuDifin is being developed as a first-in-class inflammation-modulating wound therapy to address these unmet needs
  • Development Status

    • In preclinical studies, NuDifin demonstrated superior wound healing and tissue regeneration efficacy compared to EGF
    • Phase 2 clinical trial entry targeted for 2026-2027
    • Confirmed topical stability, supporting development as a locally applied wound therapy

NuCerin

A Small but Intelligent Molecule
That Reduces Neuroinflammation and Helps Preserve Memory

  • Competitiveness

    • First-in-class GPCR19-targeting oral therapy offering superior convenience and safety compared to antibody-based treatments
    • Dual mechanism of action: Reduction of neuroinflammation + Promotion of amyloid-β (Aβ) clearance
    • No observed risk of ARIA (amyloid-related imaging abnormalities), including cerebral edema, unlike anti-Aβ antibody therapies → Suitable for long-term administration due to favorable safety profile
  • Market Outlook

    • Approximately 55 million patients worldwide with Alzheimer’s disease, projected to exceed 78 million by 2030
    • Antibody-centric markets face challenges due to high costs, injection burden, and safety concerns, creating unmet demand for alternative therapies
    • Rapid growth of next-generation oral and disease-modifying therapies focused on safety and convenience (estimated CAGR ~20%)
    • Increasing demand for long-term, orally administered treatments for early-stage and prodromal patients
  • Unmet Need

    • Existing antibody therapies suffer from high costs, safety risks, and administration inconvenience, limiting accessibility
    • Lack of orally available therapies suitable for long-term use in early-stage and mild cognitive impairment patients
    • Amyloid clearance-focused approaches alone are insufficient, highlighting the need for integrated modulation of neuroinflammation
    • NuCerin is being developed as a first-in-class, neuroinflammation-modulating oral therapy to address these gaps
  • Development Status

    • Phase 1 clinical trial ongoing in Korea (Part A completed, Part B ongoing)
    • Preclinical studies demonstrated: Improved cognitive function, Neuronal regeneration, Reduction of amyloid-β levels
    • Oral formulation with confirmed safety and stability, suitable for long-term administration

Reduction of Brain Amyloid-β Plaques and Neuroinflammation
following NuCerin Administration in an Alzheimer’s Disease Animal Model

NuCerin research data 1

Improvement in cognitive performance was observed
following NuCerin administration in an Alzheimer’s disease animal model.

NuCerin research data 2

NuSepin

Rapidly Suppressing Excessive Systemic Inflammation
to Accelerate Recovery to Daily Life in Critically Ill Patients

  • Competitiveness

    • First-in-class GPCR19-targeting intravenous anti-inflammatory therapy designed to fundamentally suppress hyperinflammatory responses, including cytokine storm
    • Simultaneous blockade of inflammatory initiation and amplification pathways, demonstrating greater efficacy than existing therapies
    • Rapid clinical response confirmed in Phase 2a, with fast onset of action and no severe adverse events observed
    • Broad potential for indication expansion, including: Severe viral pneumonia, Sepsis, COVID-19, CRS (Cytokine Release Syndrome) following immunotherapy
  • Market Outlook

    • Sustained demand for high-risk, hospitalized patient anti-inflammatory therapies, even in the post-COVID-19 era
    • WHO and CDC reports indicate persistently high mortality rates among critically ill patients, highlighting continued treatment gaps
    • Applicability across systemic inflammatory response syndrome (SIRS), pneumonia, and virus-induced hyperinflammation, supporting a market potential exceeding USD 10 billion
    • Repositioning as a rapid-response therapeutic platform for future pandemics and public health emergencies
  • Unmet Need

    • Antiviral therapies alone show limited ability to reduce immune-mediated mortality
    • Continued safety concerns with JAK/IL-6 inhibitors, including increased infection risk
    • Lack of effective treatments for severe COVID-19 and other hyperinflammatory conditions
    • NuSepin is being developed as a next-generation systemic anti-inflammatory therapy applicable across infectious and immune-mediated hyperinflammatory diseases
  • Development Status

    • Selected as a Korea Drug Development Fund (KDDF)-supported project
    • Global Phase 2b clinical trial completed

Superior improvement was observed in the NuSepin plus antiviral combination group compared to placebo.

NuSepin research data 1

NuPulin

Breaking the Vicious Cycle of Inflammation-Driven Pulmonary Fibrosis
to Help Patients Breathe More Comfortably Again

  • Competitiveness

    • First-in-class GPCR19-targeting oral therapy designed to reduce adverse events and improve long-term treatment convenience compared to existing therapies
    • Anti-fibrotic mechanism via inhibition of inflammasome activation, addressing not only disease progression but also promoting tissue recovery
    • Demonstrated efficacy comparable to existing treatments, with improvement in Ashcroft scores and reduced expression of fibrotic marker α-SMA in preclinical models
    • Selective modulation of immune cells, minimizing systemic adverse effects and supporting long-term administration
  • Market Outlook

    • Idiopathic Pulmonary Fibrosis (IPF) shows a 5-year survival rate of approximately 20%, with a global market size estimated at USD 2.5 billion
    • Among currently approved therapies, treatment discontinuation rates due to adverse events remain high (≈18%)
    • Aging populations are driving increasing prevalence and demand for safe, long-term oral therapies
    • Emergence of a new therapeutic market focused on inflammation–fibrosis dual-modulation mechanisms
  • Unmet Need

    • Existing therapies are largely limited to slowing disease progression, with minimal improvement in survival outcomes
    • Long-term treatment adherence is challenging due to gastrointestinal and other adverse effects
    • No approved therapies capable of achieving meaningful functional recovery and quality-of-life improvement
    • NuPulin is being developed as a next-generation oral therapy that simultaneously suppresses inflammation and fibrosis to address these unmet needs
  • Development Status

    • Phase 1 clinical trial ongoing in Korea (Part A completed, Part B ongoing)
    • In preclinical studies, NuPulin demonstrated suppression of pulmonary fibrosis and improvement in lung function (based on the bleomycin-induced fibrosis model)
    • Confirmed oral stability; under development as a once-daily oral formulation
  • Ashcroft Score* A semi-quantitative scale used to assess the severity of pulmonary fibrosis
  • α-SMA (alpha-smooth muscle actin)* A marker associated with myofibroblast activation and fibrosis progression

Reduction of Fibrosis-Related Markers
following NuPulin Treatment in Human Pulmonary Fibroblasts

NuPulin research data 1

Reduction in Histopathological Fibrosis Scores
following NuPulin Administration in an Idiopathic Pulmonary Fibrosis Animal Model

NuPulin research data 2
  • Vehicle A: Control group for comparator treatment
  • Vehicle B: Control group for NuPulin treatment
  • Bleomycin: A pulmonary fibrosis-inducing agent
  • Ashcroft Score: A semi-quantitative scale used to assess the severity of pulmonary fibrosis

Papiliximab

Setting a new standard for leukemia care by combining
enhanced anti-cancer efficacy with a reduced anemia risk.

  • Competitiveness

    • World’s first bispecific NanoMab simultaneously targeting PD-L1 and CD47
    • Maximizes tumor cell elimination by effectively neutralizing immune evasion mechanisms in cancer cells
    • Addresses anemia, the most critical adverse effect associated with conventional CD47 antibody therapies
    • Demonstrated favorable safety profile in non-human primate studies and superior tumor growth inhibition in vivo compared to existing antibodies
    • Small, high-stability nanobody format enables scalable manufacturing and reduced production costs
  • Market Outlook

    • The global bispecific antibody market is projected to grow from USD 18 billion in 2025 to USD 48.5 billion by 2034
    • The global acute myeloid leukemia (AML) market is expected to grow at a CAGR exceeding 10%, reaching approximately USD 10 billion by 2028
    • Despite strong interest, CD47-based immunotherapies have faced commercialization delays due to hematologic toxicities
    • Rapid expansion of the next-generation immuno-oncology market focused on safe immune activation
  • Unmet Need

    • Existing anti-PD-L1 monotherapies show limited response rates and resistance issues
    • Many CD47 antibodies have been discontinued due to severe anemia and hemagglutination-related toxicities
    • Strong demand for safe bispecific or novel-format immunotherapies
    • Papiliximab is positioned as a next-generation bispecific immuno-oncology candidate designed to overcome these limitations
  • Development Status

    • Preclinical development completed
    • In humanized mouse models of AML and lymphoma, Papiliximab demonstrated:
    • Superior tumor growth inhibition compared to comparator groups
    • More than five-fold improvement in overall survival
    • Non-human primate studies confirmed:
    • No red blood cell binding
    • No hemagglutination
    • Favorable pharmacokinetic (PK) stability
    • Strategically positioned as the first clinical entry candidate leveraging Shaperon’s bispecific NanoMab platform

Superior Tumor Growth Inhibition and Extended Survival
following Papiliximab Administration in a Humanized Lymphoma Mouse Model

Papiliximab research data 1
Papiliximab research data 2

Confirming Mitigation of Hemolytic Toxicity Associated with Conventional CD47 Antibodies

Papiliximab research data 3

Preparing

We are currently preparing the detail page.
Thank you.